A facile doxorubicin-dichloroacetate conjugate nanomedicine with high drug loading for safe drug delivery
Authors Yang CL, Wu TT, Qin YT, Qi Y, Sun Y, Kong M, Jiang X, Qin XY, Shen YQ, Zhang ZP
Received 17 October 2017
Accepted for publication 18 January 2018
Published 6 March 2018 Volume 2018:13 Pages 1281—1293
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Lei Yang
Conglian Yang,1 Tingting Wu,1 Yuting Qin,1 Yan Qi,1 Yu Sun,1 Miao Kong,1 Xue Jiang,1 Xianya Qin,1 Yaqi Shen,2 Zhiping Zhang1,3,4
1Tongji School of Pharmacy, 2Department of Radiology, Tongji Hospital, Tongji Medical College, 3National Engineering Research Center for Nanomedicine, 4Hubei Engineering Research Center for Novel Drug Delivery System, Huazhong University of Science and Technology, Wuhan, People’s Republic of China
Background: Doxorubicin (DOX) is an effective chemotherapeutic agent but severe side effects limit its clinical application. Nanoformulations can reduce the toxicity while still have various limitations, such as complexity, low drug loading capability and excipient related concerns.
Methods: An amphiphilic conjugate, doxorubicin-dichloroacetate, was synthesized and the corresponding nanoparticles were prepared. The in vitro cytotoxicity and intracellular uptake, in vivo imaging, antitumor effects and systemic toxicities of nanoparticles were carried out to evaluate the therapeutic efficiency of tumor.
Results: Doxorubicin-dichloroacetate conjugate can self-assemble into nanoparticles with small amount of DSPE-PEG2000, leading to high drug loading (71.8%, w/w) and diminished excipient associated concerns. The nanoparticles exhibited invisible systemic toxicity and high maximum tolerated dose of 75 mg DOX equiv./kg, which was 15-fold higher than that of free DOX. It also showed good tumor targeting capability and enhanced antitumor efficacy in murine melanoma model.
Conclusion: This work provides a promising strategy to simplify the drug preparation process, increase drug loading content, reduce systemic toxicity as well as enhance antitumor efficiency.
Keywords: self-assembly, doxorubicin, drug delivery, chemotherapy, nanomedicine
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]